-+ 0.00%
-+ 0.00%
-+ 0.00%

Teva wins FDA approval for IGALMI as first at-home treatment for agitation in adults with schizophrenia or bipolar disorder

PUBT·11/16/2026 13:02:06
Listen to the news
Teva wins FDA approval for IGALMI as first at-home treatment for agitation in adults with schizophrenia or bipolar disorder
  • Teva received FDA approval for IGALMI as the first at-home treatment for agitation in adults.
  • The approval covers agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
  • Reported Phase 3 SERENITY results met the primary safety and tolerability endpoint, with no treatment discontinuations due to tolerability.
  • Tolerability remained consistent with repeat dosing during the 12-week study.
  • IGALMI was acquired in late October 2026; commercialization plans for at-home use will be announced later.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800OMX_____CNEWS_EN_GNW1001303832_en) on November 16, 2026, and is solely responsible for the information contained therein.